Answers are grounded in this paper and cite their sources.
Purpose: Brexpiprazole, when administered with antidepressant therapy, may provide additional benefits due to complementary actions on noradrenaline (norepinephrine), serotonin, and dopamine neurotransmitter systems. This review addressed the question: what information can preclinical studies provide on the use of brexpiprazole + antidepressant treatment? Methods: A systematic literature review was conducted to search for preclinical studies of brexpiprazole + antidepressant therapy that included a behavioral test relating to any psychiatric disorder. Ovid MEDLINE, Ovid Embase, and conference abstracts were searched (January 1, 2011–July 5, 2021). The statistically significant (p< 0.05) findings for brexpiprazole + antidepressant were extracted. Results: Of 296 records screened, nine articles were eligible, describing seven unique studies. In rodent models, including three models of depression (unpredictable chronic mild stress, social defeat stress, and lipopolysaccharide-induced depression), brexpiprazole + selective serotonin reuptake inhibitor (SSRI) or serotonin–noradrenaline reuptake inhibitor (SNRI) consistently showed statistically significant benefits over vehicle on depression-like behaviors (forced swim test, tail suspension test, sucrose preference), whereas brexpiprazole and antidepressant monotherapies did not. In the predator scent stress model of post-traumatic stress disorder (PTSD), brexpiprazole + SSRI (escitalopram) showed a significant benefit over vehicle and/or monotherapy on anxiety-like behaviors (elevated plus-maze) and hyperalertness (acoustic startle response), whereas brexpiprazole and escitalopram monotherapies did not significantly differ from vehicle. In the fear conditioning model of PTSD, brexpiprazole showed significant improvements whether administered as monotherapy or in combination with escitalopram. Conclusion: Based on a small number of studies, the administration of brexpiprazole with an antidepressant appears to have a greater treatment effect than either brexpiprazole or antidepressant monotherapies in preclinical studies of depression- and PTSD-like behaviors. Thus, preclinical studies support evidence from randomized clinical trials for the therapeutic effects of adjunctive brexpiprazole in the treatment of major depressive disorder, and brexpiprazole in combination with sertraline in the treatment of PTSD. Funding: Otsuka/Lundbeck. Plain Language Summary: Studies of medications in animals can provide additional information to complement studies in humans. This review investigates what can be learned from animal studies of brexpiprazole (a medication known as an “atypical antipsychotic”) given together with an antidepressant medication. Seven animal studies that assess brexpiprazole + antidepressant treatment in rat or mouse models of depression and post-traumatic stress disorder were identified. Overall, these animal studies provide support for the observed benefits of brexpiprazole added to antidepressant treatment in major depressive disorder, and the ongoing development of brexpiprazole + antidepressant as a potential combination treatment for post-traumatic stress disorder.
No takes yet. Share an insight, caveat, or question.
Brubaker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: